VSV-EBOVAC identifies signature of promising Ebola vaccine
How exactly does our immune system respond to vaccination? In the first study of its kind, scientists from IMI's VSV-EBOVAC project, studying a promising Ebola vaccine, set out to find out which immune cells get activated early on, which inflammatory markers are released after that, and how this early activity later impacts the production of antibodies against the Ebola virus. In the process, they discovered a unique signature of a promising Ebola vaccine candidate which could not only help predict adverse reactions and effectiveness of this vaccine, but also inform the development of vaccines for other diseases as well.
Read more here.